Bausch + Lomb’s sudden CEO change has pushed its unresolved independence question back to the center of the investment case, after parent Bausch Health retained control following the company’s 2022 listing and a potential sale process ended without a deal in 2025.
Bausch + Lomb and Bausch Health said Monday that Thomas J. Appio, chairman of Bausch + Lomb’s board, was appointed interim chief executive of the eye-care company, effective immediately. Appio will also continue as CEO of Bausch Health, which controls Bausch + Lomb through its majority stake.1 Brent Saunders, who had led Bausch + Lomb since 2023, and the board mutually agreed that he would leave the company, the companies said.1
For healthcare deal watchers, the significance is less the interim title than the structure: one executive now runs both the listed subsidiary and its controlling shareholder. Reuters reported that Bausch Health still owns about 87% of Bausch + Lomb, after separating the eye-care business into a public company in 2022 while retaining control.4 Reuters also reported that a potential sale process ended without a deal in 2025.3
The arrangement gives the parent company a clearer chain of command. It also sharpens questions about Bausch + Lomb’s strategic independence, including who sets priorities for capital allocation, transaction timing and any future reduction of Bausch Health’s stake. Finimize said investors are now weighing leadership and governance together, noting that the parent’s roughly 87% position can create a minority-shareholder discount when major decisions remain with the controller.10
Governance returns to the foreground
Bausch + Lomb’s leadership announcement did not name a permanent successor or describe a new strategic review. The company said Appio had been appointed board chairman in August 2026 and cited his prior Bausch + Lomb roles, including managing director for China and president of Bausch + Lomb International, as reasons he was positioned to lead the business through its next phase.1
That operating familiarity may reassure investors focused on execution. But it also makes the leadership change difficult to separate from Bausch Health’s ownership agenda. Reuters reported that Leerink analysts said the sudden change could weigh on the stock as investors focus on Bausch Health’s plans for its Bausch + Lomb stake. The analysts also said the eye-care company remained on solid fundamentals.4
Fierce Pharma reported that the transition surprised analysts, citing Bausch + Lomb’s bullish targets at a late-2025 investor event. It also noted that Appio’s temporary appointment could indicate the move was unexpected for the company as well.5
Sale overhang remains after 2025 process
The CEO change comes less than a year after the failed sale process left Bausch + Lomb in a hybrid position: publicly traded and operationally separate in many respects, but still controlled by Bausch Health. For potential buyers, that history matters.
A new process would need to answer whether Bausch Health is motivated to sell, whether the parent would consider partial monetization instead, and how much governance autonomy a buyer or public-market minority investor could expect before any transaction.
The failed 2025 process also changes how investors may read interim management. An independent permanent CEO could have been seen as a sign that Bausch + Lomb was continuing to build a standalone identity. By contrast, Appio’s dual role may be interpreted as tighter parent oversight, at least until the board names a permanent chief executive or Bausch Health provides more detail on its long-term ownership plan.
That does not mean a transaction is imminent or off the table. It does mean the central deal question has shifted from whether Bausch + Lomb can operate as a listed eye-care company to whether its controller intends to maintain, reduce or exit its stake — and on what terms.
Shares fell despite stronger guidance signal
The governance concern outweighed a favorable operating signal in the immediate market reaction. Bausch + Lomb and Bausch Health said they expected to raise full-year 2026 adjusted EBITDA guidance, excluding acquired in-process research and development, based on preliminary third-quarter results. Details are due when both companies report third-quarter results on Oct. 28.1
Business Wire’s version of the company announcement said the expected guidance increase reflected continued strong third-quarter business performance and anticipated stronger performance for the rest of 2026.2 Benzinga reported that Bausch + Lomb’s U.S.-listed shares were down nearly 10% Monday afternoon, while Bausch Health shares were down a little more than 2% at the time of publication.6
Reuters reported a decline of more than 7% in Bausch + Lomb’s U.S.-listed shares and said the company did not disclose the reason for Saunders’ departure.4 The company did not immediately respond to a Reuters request for comment, according to the report.4
What deal watchers will look for next
The next signposts are likely to be less about near-term sales of contact lenses, surgical devices or pharmaceuticals and more about governance mechanics. Investors will look for whether Bausch + Lomb names an independent permanent CEO, whether Appio’s interim mandate comes with a defined timeline, and whether the board says anything more about minority-shareholder protections or strategic alternatives.
The Oct. 28 results call may also test how far management is willing to go in discussing ownership. A guidance raise could support the argument that Bausch + Lomb’s business trajectory remains intact. But without clarity on Bausch Health’s 87% stake, the company may continue to trade not only on operating performance but also on the market’s view of parent-company control.10
For now, Appio’s appointment links the parent and subsidiary more visibly than at any point since Bausch + Lomb’s listing. That makes the company’s next governance moves central to any assessment of whether Bausch + Lomb is moving toward fuller strategic independence or settling into a controlled-company structure after the failed 2025 sale effort.
Comments